Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 33 (7-8), 3241-3244
- https://doi.org/10.1016/s0041-1345(01)02378-8
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Cytomegalovirus Infection and Abdominal Pain with Mycophenolate MofetilDrug Safety, 2001
- The use of mycophenolate mofetil in transplant recipientsImmunopharmacology, 2000
- A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1Transplantation, 1999
- FOUR-YEAR FOLLOW-UP OF MYCOPHENOLATE MOFETIL FOR GRAFT RESCUE IN LIVER ALLOGRAFT RECIPIENTS1Transplantation, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*Clinical Pharmacology & Therapeutics, 1998
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Mechanisms of Action of New Immunosuppressive DrugsTherapeutic Drug Monitoring, 1995
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995